1375 related articles for article (PubMed ID: 32901936)
1. Targeted therapy strategies against SARS-CoV-2 cell entry mechanisms: A systematic review of in vitro and in vivo studies.
Seyedpour S; Khodaei B; Loghman AH; Seyedpour N; Kisomi MF; Balibegloo M; Nezamabadi SS; Gholami B; Saghazadeh A; Rezaei N
J Cell Physiol; 2021 Apr; 236(4):2364-2392. PubMed ID: 32901936
[TBL] [Abstract][Full Text] [Related]
2. Distinctive Roles of Furin and TMPRSS2 in SARS-CoV-2 Infectivity.
Essalmani R; Jain J; Susan-Resiga D; Andréo U; Evagelidis A; Derbali RM; Huynh DN; Dallaire F; Laporte M; Delpal A; Sutto-Ortiz P; Coutard B; Mapa C; Wilcoxen K; Decroly E; Nq Pham T; Cohen ÉA; Seidah NG
J Virol; 2022 Apr; 96(8):e0012822. PubMed ID: 35343766
[TBL] [Abstract][Full Text] [Related]
3. Targeting the viral-entry facilitators of SARS-CoV-2 as a therapeutic strategy in COVID-19.
Muralidar S; Gopal G; Visaga Ambi S
J Med Virol; 2021 Sep; 93(9):5260-5276. PubMed ID: 33851732
[TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2 Spike Furin Cleavage Site and S2' Basic Residues Modulate the Entry Process in a Host Cell-Dependent Manner.
Lavie M; Dubuisson J; Belouzard S
J Virol; 2022 Jul; 96(13):e0047422. PubMed ID: 35678602
[TBL] [Abstract][Full Text] [Related]
5. Research Progress on Spike-Dependent SARS-CoV-2 Fusion Inhibitors and Small Molecules Targeting the S2 Subunit of Spike.
Freidel MR; Armen RS
Viruses; 2024 Apr; 16(5):. PubMed ID: 38793593
[TBL] [Abstract][Full Text] [Related]
6. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
Li K; Meyerholz DK; Bartlett JA; McCray PB
mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553
[TBL] [Abstract][Full Text] [Related]
7. Withanone from
Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
[TBL] [Abstract][Full Text] [Related]
8. Nonmuscle myosin heavy chain IIA facilitates SARS-CoV-2 infection in human pulmonary cells.
Chen J; Fan J; Chen Z; Zhang M; Peng H; Liu J; Ding L; Liu M; Zhao C; Zhao P; Zhang S; Zhang X; Xu J
Proc Natl Acad Sci U S A; 2021 Dec; 118(50):. PubMed ID: 34873039
[TBL] [Abstract][Full Text] [Related]
9. Structural Basis for the Understanding of Entry Inhibitors against SARS Viruses.
Kushwaha PK; Kumari N; Nayak S; Kishor K; Sharon A
Curr Med Chem; 2022; 29(4):666-681. PubMed ID: 33992054
[TBL] [Abstract][Full Text] [Related]
10. Genome-wide bioinformatics analysis of human protease capacity for proteolytic cleavage of the SARS-CoV-2 spike glycoprotein.
Matveev EV; Ponomarev GV; Kazanov MD
Microbiol Spectr; 2024 Feb; 12(2):e0353023. PubMed ID: 38189333
[TBL] [Abstract][Full Text] [Related]
11. Exploring SARS-CoV-2 Spikes Glycoproteins for Designing Potential Antiviral Targets.
Kamel NA; El Wakeel LM; Aboshanab KM
Viral Immunol; 2021 Oct; 34(8):510-521. PubMed ID: 34018828
[TBL] [Abstract][Full Text] [Related]
12. Calpain-2 mediates SARS-CoV-2 entry via regulating ACE2 levels.
Zeng Q; Antia A; Casorla-Perez LA; Puray-Chavez M; Kutluay SB; Ciorba MA; Ding S
mBio; 2024 Mar; 15(3):e0228723. PubMed ID: 38349185
[TBL] [Abstract][Full Text] [Related]
13. A substrate for a cell free in vitro assay system to screen drugs targeting trypsin like protease-based cleavage of SARS-CoV-2 spike glycoprotein and viral entry.
Begum F; Srivastava AK; Tripathi PP; Ray U
J Med Virol; 2023 May; 95(5):e28796. PubMed ID: 37218551
[TBL] [Abstract][Full Text] [Related]
14. Potential inhibitors of SARS-CoV-2: recent advances.
Jamalipour Soufi G; Iravani S
J Drug Target; 2021 Apr; 29(4):349-364. PubMed ID: 33210953
[TBL] [Abstract][Full Text] [Related]
15. Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants.
Acharya A; Pandey K; Thurman M; Klug E; Trivedi J; Sharma K; Lorson CL; Singh K; Byrareddy SN
J Virol; 2021 Nov; 95(24):e0143721. PubMed ID: 34550770
[TBL] [Abstract][Full Text] [Related]
16. Effect of clinical isolate or cleavage site mutations in the SARS-CoV-2 spike protein on protein stability, cleavage, and cell-cell fusion.
Barrett CT; Neal HE; Edmonds K; Moncman CL; Thompson R; Branttie JM; Boggs KB; Wu CY; Leung DW; Dutch RE
J Biol Chem; 2021 Jul; 297(1):100902. PubMed ID: 34157282
[TBL] [Abstract][Full Text] [Related]
17. An Updated Review on Betacoronavirus Viral Entry Inhibitors: Learning from Past Discoveries to Advance COVID-19 Drug Discovery.
Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA
Curr Top Med Chem; 2021; 21(7):571-596. PubMed ID: 33463470
[TBL] [Abstract][Full Text] [Related]
18. Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2).
Xiang Y; Wang M; Chen H; Chen L
Biochem Pharmacol; 2021 Oct; 192():114724. PubMed ID: 34371003
[TBL] [Abstract][Full Text] [Related]
19. Reactive Centre Loop Mutagenesis of SerpinB3 to Target TMPRSS2 and Furin: Inhibition of SARS-CoV-2 Cell Entry and Replication.
Singh S; O'Reilly S; Gewaid H; Bowie AG; Gautier V; Worrall DM
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293378
[TBL] [Abstract][Full Text] [Related]
20. Metalloproteinase-Dependent and TMPRSS2-Independent Cell Surface Entry Pathway of SARS-CoV-2 Requires the Furin Cleavage Site and the S2 Domain of Spike Protein.
Yamamoto M; Gohda J; Kobayashi A; Tomita K; Hirayama Y; Koshikawa N; Seiki M; Semba K; Akiyama T; Kawaguchi Y; Inoue JI
mBio; 2022 Aug; 13(4):e0051922. PubMed ID: 35708281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
